Loading
Life sciences · Journal article
International Journal of Pharmaceutics: X · August 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Osteoarthritis is a whole-joint disease characterized by persistent inflammation, immune dysregulation, oxidative stress, cellular senescence, and impaired cartilage repair. Current treatments remain largely symptomatic, underscoring the need for disease-modifying strategies that can reshape the pathological joint microenvironment. Nanoimmunomodulation offers a promising approach by combining targeted intra-articular delivery, controlled release, biomimetic design, and immune reprogramming. In this Review, we discuss how nanoplatforms, including polymeric nanoparticles, lipid vesicles, inorganic nanozymes, extracellular vesicle-inspired systems, cell-membrane-coated nanoparticles, and hydrogel-nanoparticle composites, regulate synovial macrophage polarization, inflammasome activation, ROS accumulation, mitochondrial dysfunction, ferroptosis, cellular senescence, and cartilage matrix catabolism. We further propose a translational framework linking nanomaterial design to disease-stage-specific immune phenotypes, joint retention, cartilage penetration, safety, manufacturability, and clinically meaningful endpoints. While nanoimmunomodulation offers a compelling preclinical rationale for targeting multiple pathological drivers simultaneously, its translation into clinically validated disease-modifying therapy remains contingent upon overcoming significant hurdles in safety, manufacturing, and regulatory endpoint alignment. This review proposes a phenotype-driven framework to guide future clinical development rather than asserting imminent clinical efficacy.